In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk for falls, and combined use with GLP-1 RAs nearly tripled the risk.
In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk for falls, and combined use with GLP-1 RAs nearly tripled the risk.